Antiminth (pyrantel pamoate).
D000293:Adolescent; D000328:Adult; D000724:Ancylostomiasis / Q000188:drug therapy; D000818:Animals; D001196:Ascariasis / Q000188:drug therapy; D055598:Chemical Phenomena; D002621:Chemistry; D002648:Child; D004341:Drug Evaluation; D005260:Female; D006725:Hookworm Infections / Q000188:drug therapy; D006801:Humans; D007928:Lethal Dose 50; D008297:Male; D008875:Middle Aged; D009349:Nematode Infections / Q000188:drug therapy*; D010123:Oxyuriasis / Q000188:drug therapy; D011715:Pyrantel / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use* / Q000633:toxicity; D012995:Solubility; D013644:Tartrates; D014257:Trichuriasis / Q000188:drug therapy
D013644:Tartrates; D011715:Pyrantel